Abstracts of the 11th Congress of ECCO - European Crohn’s and Colitis Organisation
S167
Table 1 Zinc deficiency and IBD-related clinical outcomes in UC
At least 1 UC-related
hospitalisation
Odds ratio for low zinc vs
normal zinc (95% confidence interval [CI])
Unadjusted
2.93 (1.61, 5.35)***
Adjusted 1
3.05 (1.52, 6.13)**
Adjusted 2
2.07 (0.98, 4.36)
1 Adjusted for gender, race,
use of anti-tumour necrosis
factor (TNF) or immunomodulators, age, and
duration of disease
P-value
At least 1 UC-related P-value
surgery
P < 0.001
3.48 (1.65, 7.51)**
P < 0.01
3.32 (1.42, 7.80)**
0.055
2.22 (0.91, 5.44)
2 Adjusted for gender,
race, use of anti-TNF or
immunomodulators, age,
duration of disease, and
albumin
[6] Ranaldi G. Intracellular zinc is required for intestinal cell survival signals triggered by the inflammatory cytokine TNF-α. J Nutr Biochem
2013;24(6):967–76.
[7] Bonaventura PBenedetti G1, Albarède F, et al. (2015), Zinc and its role in
immunity and inflammation. Autoimmun Rev 2015;14(4):277–85.
P152
Faecal calprotectin 100 ug/g and 50 ug/g
predict endoscopic and histologic remission: a
prospective study in quiescent ulcerative colitis
H. Y. Shi*, F. K. Chan, A. Higashimori, A. Chan, J. Y. Ching, J. C.
Wu, J. J. Sung, S. C. Ng
The Chinese University of Hong Kong, Hong Kong, China
Background: Faecal calprotectin (FC) level correlates with mucosal
inflammation. However, cut-off values of FC in identifying endoscopic and histologic remission in patients with quiescent ulcerative
colitis (UC) remain unclear.
Methods: In this prospective study, consecutive adult patients with
quiescent UC (defined as a Mayo stool frequency sub-score of 0 or 1,
and a Mayo rectal bleeding subs-core of 0) underwent colonoscopy
and had biopsies collected from each colonic segment. Endoscopic
remission was defined as Mayo endoscopic sub-score ≤ 1. Histologic
remission was defined as Geboes score < 2.0. The highest score
amongst different segments of each patient was used for analysis. FC was determined by enzyme-linked immunosorbent assay.
Circulating markers (white blood cell count, haemoglobin, platelet
count, C-reactive protein [CRP], and erythrocyte sedimentation rate)
were measured and correlated with endoscopic and histologic scores.
Results: Enrolled were75 UC patients (54.7% male; median age
50 years). Endoscopic remission and histologic remission were seen
in 63 (84.0%) and 35 (57.4%) patients, respectively. FC identified
endoscopic remission with an area under the receiver operator characteristic curve (AUC) value of 0.824 (p = 0.006). The sensitivity
and specificity of FC < 100ug/g to detect endoscopic remission were
77.8% and 85.7%, respectively. Endoscopic remission was achieved
in 97.7% of patients with a FC level < 100ug/g (vs 66.7% of patients
with FC level ≥ 100ug/g, p = 0.002). FC identified histologic remission with an AUC value of 0.742 (p = 0.003). The sensitivity, specificity, positive predictive value and negative predictive value of FC
level < 50ug/g to identify histologic remission were 89.6%, 69.6%,
78.8%, and 84.2%, respectively. Histologic remission was achieved
in 78.8% of patients with FC level < 50ug/g (vs 15.8% of those
with FC level ≥ 50ug/g, p < 0.001). CRP correlated significantly
with endoscopic remission (AUC = 0.697, p = 0.039), but not with
At least 1 UC-related P-value
complication
P < 0.01 1.94 (1.12, 3.37)*
P < 0.01 2.18 (1.16, 4.10)*
0.081 1.75 (0.90, 3.42)
P < 0.05
P < 0.05
0.10
histologic remission. Other circulating markers were not significant
correlated with neither endoscopic nor histologic remission.
Conclusions: Level of FC at < 100 ug/g and < 50 ug/g reliably identified UC patients who had endoscopic and histologic remission,
respectively. If colonoscopy is performed only in patients with FC
level ≥ 50 ug/g, colonoscopy could be avoided in up to 90% of quiescent UC patients with histologic remission.
P153
Type of treating physician is associated with
long-term disease outcome in the prospective
Belgian paediatric Crohn’s disease registry
L. Wauters*1, F. Smets2, E. De Greef3, P. Bontems4, I. Hoffman5,
B. Hauser3, P. Alliet6, W. Arts7, H. Peeters8, S. Van Biervliet9,
I. Paquot10, E. Van de Vijver11, M. De Vos12, P. Bossuyt13, J.-F.
Rahier14, O. Dewit15, T. Moreels15, D. Franchimont16, V. Muls16,
F. Fontaine17, E. Louis17, J.-C. Coche18, J. Paul19, F. Baert20,
S. Vermeire1, G. Veereman3
1
UZ Leuven, Gastroenterology and Hepatology, Leuven, Belgium,
2
UCL St Luc, Paediatric Gastroenterology, Brussels, Belgium,
3
UZ Brussel, Paediatric Gastroenterology, Brussels, Belgium,
4
HUDERF, Paediatric Gastroenterology, Brussels, Belgium,
5
UZ Leuven, Paediatric Gastroenterology, Leuven, Belgium,
6
Jessa ziekenhuis, Paediatric Gastroenterology, Hasselt, Belgium,
7
ZOL Genk, Paediatric Gastroenterology, Genk, Belgium, 8ST
Lucas, Gastroenterology, Ghent, Belgium, 9UZ Gent, Paediatric
Gastroenterology, Ghent, Belgium, 10CHC Liège, Paediatric
Gastroenterology, Liège, Belgium, 11UZ Antwerpen, Paediatric
Gastroenterology, Antwerp, Belgium, 12UZ Gent, Gastroenterology,
Ghent, Belgium, 13Imelda ziekenhuis, Gastroenterology, Bonheiden,
Belgium, 14UCL Mont Godinne, Gastroenterology, Mont Godinne,
Belgium, 15UCL St Luc, Gastroenterology, Brussels, Belgium,
16
ULB Erasme, Gastroenterology, Brussels, Belgium, 17CHU Liège,
Gastroenterology, Liège, Belgium, 18St Pierre, Gastroenterology,
Ottignies, Belgium, 19DNA Lytics, Brussels, Belgium, 20Heilig Hart
Ziekenhuis, Gastroenterology, Roeselaere, Belgium
Background: Treatment and outcomes in paediatric Crohn’s disease
(CD) have not been compared between type of treating physician
and centre of care.
Methods: Data from the Belgian paediatric Crohn’s disease registry
(BELCRO), an observational prospective cohort of children (< 18
yr) diagnosed with CD in Belgium, were analysed. Disease severity
was scored as inactive, mild, and moderate-to-severe, using a 3-point
scale and monitored yearly. Response was defined as a decrease of